Maravai Lifesciences Holdings (MRVI) Cash from Financing Activities (2020 - 2026)

Maravai Lifesciences Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$55.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 1027.06% year-over-year to -$55.2 million in Q1 2026; TTM through Mar 2026 was -$66.8 million, a 72.16% increase from a year earlier, with the FY2025 full-year figure at -$16.5 million, up 93.0% from the prior year.
• Cash from Financing Activities eased to -$55.2 million in Q1 2026 per MRVI's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $809000.0 in Q3 2024 and bottomed at -$236.2 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$8.2 million (2025), against an average of -$32.7 million.
• Across the five-year window, Cash from Financing Activities soared 102.09% in 2023 and plunged 50352.98% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$66.1 million in 2022, then soared by 100.71% to $470000.0 in 2023, then plunged by 50352.98% to -$236.2 million in 2024, then jumped by 99.23% to -$1.8 million in 2025, then tumbled by 2941.08% to -$55.2 million in 2026.
• Per Business Quant, the three latest MRVI Cash from Financing Activities figures stand at -$55.2 million (Q1 2026), -$1.8 million (Q4 2025), and -$8.2 million (Q3 2025).